ARDS Part IISpecial Guest: Steven Lemieux, PharmD, BCPS, BCCCP03:45 – ESICM guidelines and ARDS definition11:50 – Phenotypes and respiratory support23:50 – Corticosteroids34:40 – NMBA, pulmonary vasodilators, and VV ECMO44:00 - Fun facts and take-home pointsReference List: https://pharmacytodose.files.wordpress.com/2023/08/ards-part-ii-references.pdfPharmacyToDose.Com @PharmacyToDose PharmacyToDose@Gmail.com Learn more about your ad choices. Visit megaphone.fm/adchoices

ARDS Part IISpecial Guest: Steven Lemieux, PharmD, BCPS, BCCCP 03:45 – ESICM guidelines and ARDS definition11:50 – Phenotypes and respiratory support23:50 – Corticosteroids34:40 – NMBA, pulmonary vasodilators, and VV ECMO44:00 - Fun facts and take-home points Reference List: <a href="https://pharmacytodose.files.wordpress.com/2023/08/ards-part-ii-references.pdf" rel="nofollow" target="_blank">https://pharmacytodose.files.wordpress.com/2023/08/ards-part-ii-references.pdf</a> <a href="http://PharmacyToDose.Com" rel="nofollow" target="_blank">PharmacyToDose.Com</a> @PharmacyToDose <a href="mailto:PharmacyToDose@Gmail.com">PharmacyToDose@Gmail.com</a> Learn more about your ad choices. Visit <a href="https://megaphone.fm/adchoices" rel="nofollow" target="_blank">megaphone.fm/adchoices</a>

ARDS Part II

Trial of the Week: CATSSpecial Guest: Scott Benken, PharmD, MHPE, BCPS-AQ Cardiology, FCCM, FCCPScott Benken joins me to discuss the upcoming 2023 Chicagoland Critical Care Conference before reviewing the 2007 CATS study which compares catecholamine vasopressors and inotropes in septic shock. We cover the history of septic shock treatment, review the study results, current guideline recommendations, and much more.2023 Chicagoland Critical Care Conference registration link:https://appserv7.admin.uillinois.edu/FormBuilderSurvey/Survey/uic_college_of_pharmacy/continuing_education/critical_care_2023/SurveyReference list: https://pharmacytodose.files.wordpress.com/2023/08/cats-trial-of-week-references.pdfPharmacyToDose.Com @PharmacyToDose PharmacyToDose@Gmail.com Learn more about your ad choices. Visit megaphone.fm/adchoices

Trial of the Week: CATS Special Guest: Scott Benken, PharmD, MHPE, BCPS-AQ Cardiology, FCCM, FCCP Scott Benken joins me to discuss the upcoming 2023 Chicagoland Critical Care Conference before reviewing the 2007 CATS study which compares catecholamine vasopressors and inotropes in septic shock. We cover the history of septic shock treatment, review the study results, current guideline recommendations, and much more. 2023 Chicagoland Critical Care Conference registration link:<a href="https://appserv7.admin.uillinois.edu/FormBuilderSurvey/Survey/uic_college_of_pharmacy/continuing_education/critical_care_2023/Survey" rel="nofollow" target="_blank">https://appserv7.admin.uillinois.edu/FormBuilderSurvey/Survey/uic_college_of_pharmacy/continuing_education/critical_care_2023/Survey</a> Reference list: <a href="https://pharmacytodose.files.wordpress.com/2023/08/cats-trial-of-week-references.pdf" rel="nofollow" target="_blank">https://pharmacytodose.files.wordpress.com/2023/08/cats-trial-of-week-references.pdf</a> <a href="http://PharmacyToDose.Com" rel="nofollow" target="_blank">PharmacyToDose.Com</a> @PharmacyToDose <a href="mailto:PharmacyToDose@Gmail.com">PharmacyToDose@Gmail.com</a> Learn more about your ad choices. Visit <a href="https://megaphone.fm/adchoices" rel="nofollow" target="_blank">megaphone.fm/adchoices</a>

Trial of the Week: CATS

Trial of the Week: Unpeeling the Banana BagSpecial Guests: Aaron Cook, PharmD, FCCP, FNCS, FKSHP, BCCCP, BCPSAlex Flannery, PharmD, PhD, FCCM, BCCCP, BCPSListen to Aaron and Alex go into the history of this famous article, discuss how this paper, and how they still feel the impact years after publication.Flannery AH, Adkins DA, Cook AM. Unpeeling the Evidence for the Banana Bag: Evidence-Based Recommendations for the Management of Alcohol-Associated Vitamin and Electrolyte Deficiencies in the ICU. Crit Care Med. 2016 Aug;44(8):1545-52. https://pubmed.ncbi.nlm.nih.gov/27002274/PharmacyToDose.Com @PharmacyToDose PharmacyToDose@Gmail.com Learn more about your ad choices. Visit megaphone.fm/adchoices

Trial of the Week: Unpeeling the Banana Bag Special Guests: Aaron Cook, PharmD, FCCP, FNCS, FKSHP, BCCCP, BCPSAlex Flannery, PharmD, PhD, FCCM, BCCCP, BCPS Listen to Aaron and Alex go into the history of this famous article, discuss how this paper, and how they still feel the impact years after publication. Flannery AH, Adkins DA, Cook AM. Unpeeling the Evidence for the Banana Bag: Evidence-Based Recommendations for the Management of Alcohol-Associated Vitamin and Electrolyte Deficiencies in the ICU. Crit Care Med. 2016 Aug;44(8):1545-52. <a href="https://pubmed.ncbi.nlm.nih.gov/27002274/" rel="nofollow" target="_blank">https://pubmed.ncbi.nlm.nih.gov/27002274/</a> <a href="http://PharmacyToDose.Com" rel="nofollow" target="_blank">PharmacyToDose.Com</a> @PharmacyToDose <a href="mailto:PharmacyToDose@Gmail.com">PharmacyToDose@Gmail.com</a> Learn more about your ad choices. Visit <a href="https://megaphone.fm/adchoices" rel="nofollow" target="_blank">megaphone.fm/adchoices</a>

Trial of the Week: Unpeeling the Banana Bag

Rapid Reaction: MERCYSpecial Guests: Erin McCreary, PharmD, BCPS, BCIDPJason Pogue, PharmD, BCPS, BCIDP11:00 – Background, study methodology, and results23:00 – MERCY deep-dive, discussion, and future considerationsMERCY: https://pubmed.ncbi.nlm.nih.gov/37326473/Reference List: https://pharmacytodose.files.wordpress.com/2023/08/mercy-rapid-reaction-references.pdfPharmacyToDose.Com @PharmacyToDose PharmacyToDose@Gmail.com Learn more about your ad choices. Visit megaphone.fm/adchoices

Rapid Reaction: MERCY Special Guests: Erin McCreary, PharmD, BCPS, BCIDPJason Pogue, PharmD, BCPS, BCIDP 11:00 – Background, study methodology, and results23:00 – MERCY deep-dive, discussion, and future considerations MERCY: <a href="https://pubmed.ncbi.nlm.nih.gov/37326473/" rel="nofollow" target="_blank">https://pubmed.ncbi.nlm.nih.gov/37326473/</a> Reference List: <a href="https://pharmacytodose.files.wordpress.com/2023/08/mercy-rapid-reaction-references.pdf" rel="nofollow" target="_blank">https://pharmacytodose.files.wordpress.com/2023/08/mercy-rapid-reaction-references.pdf</a> <a href="http://PharmacyToDose.Com" rel="nofollow" target="_blank">PharmacyToDose.Com</a> @PharmacyToDose <a href="mailto:PharmacyToDose@Gmail.com">PharmacyToDose@Gmail.com</a> Learn more about your ad choices. Visit <a href="https://megaphone.fm/adchoices" rel="nofollow" target="_blank">megaphone.fm/adchoices</a>

Rapid Reaction: MERCY

Literature Review SeriesMay 2023Special Guest: Kelly Oldziej, PharmD05:00 – Featured Articles36:20 – Cardiology47:20 – Infectious Diseases51:00 – Emergency Medicine59:22 – PharmD66:15 – Grab BagReference List: https://pharmacytodose.files.wordpress.com/2023/07/may-lrs-2023-references.pdfPharmacyToDose.Com @PharmacyToDose PharmacyToDose@Gmail.com Learn more about your ad choices. Visit megaphone.fm/adchoices

Literature Review SeriesMay 2023Special Guest: Kelly Oldziej, PharmD 05:00 – Featured Articles36:20 – Cardiology47:20 – Infectious Diseases51:00 – Emergency Medicine59:22 – PharmD66:15 – Grab Bag Reference List: <a href="https://pharmacytodose.files.wordpress.com/2023/07/may-lrs-2023-references.pdf" rel="nofollow" target="_blank">https://pharmacytodose.files.wordpress.com/2023/07/may-lrs-2023-references.pdf</a> <a href="http://PharmacyToDose.Com" rel="nofollow" target="_blank">PharmacyToDose.Com</a> @PharmacyToDose <a href="mailto:PharmacyToDose@Gmail.com">PharmacyToDose@Gmail.com</a> Learn more about your ad choices. Visit <a href="https://megaphone.fm/adchoices" rel="nofollow" target="_blank">megaphone.fm/adchoices</a>

May 2023 Literature Review Series

Amiodarone v. Lidocaine: Versus SeriesSpecial Guest: Matt Wanat, PharmD, BCPS, BCCCP, FCCM05:50 – Out-of-hospital cardiac arrest19:15 – In-hospital cardiac arrest32:04 – Refractory ventricular arrhythmias47:08 – Potpourri52:26 – Closing statements2023 Pharmacy to Dose Awards Ballot: https://forms.gle/9y2wTM8y8tgodvYUAReference List: https://pharmacytodose.files.wordpress.com/2023/07/amiodarone-vs-lidocaine-references.pdfPharmacyToDose.Com @PharmacyToDose PharmacyToDose@Gmail.com Learn more about your ad choices. Visit megaphone.fm/adchoices

Amiodarone v. Lidocaine: Versus SeriesSpecial Guest: Matt Wanat, PharmD, BCPS, BCCCP, FCCM 05:50 – Out-of-hospital cardiac arrest19:15 – In-hospital cardiac arrest32:04 – Refractory ventricular arrhythmias47:08 – Potpourri52:26 – Closing statements 2023 Pharmacy to Dose Awards Ballot: <a href="https://forms.gle/9y2wTM8y8tgodvYUA" rel="nofollow" target="_blank">https://forms.gle/9y2wTM8y8tgodvYUA</a> Reference List: <a href="https://pharmacytodose.files.wordpress.com/2023/07/amiodarone-vs-lidocaine-references.pdf" rel="nofollow" target="_blank">https://pharmacytodose.files.wordpress.com/2023/07/amiodarone-vs-lidocaine-references.pdf</a> <a href="http://PharmacyToDose.Com" rel="nofollow" target="_blank">PharmacyToDose.Com</a> @PharmacyToDose <a href="mailto:PharmacyToDose@Gmail.com">PharmacyToDose@Gmail.com</a> Learn more about your ad choices. Visit <a href="https://megaphone.fm/adchoices" rel="nofollow" target="_blank">megaphone.fm/adchoices</a>

Amiodarone v Lidocaine: Versus Series

COPDSpecial Guest: Ty Kiser, PharmD, FCCM, FCCP, BCCCP, BCPS03:15 – Background &amp; classification07:10 – AECOPD13:00 – Pharmacotherapy in AECOPD32:40 – Maintenance medications41:55 – Future research / wrap-up 2023 Pharmacy to Dose Awards Ballot: https://forms.gle/9y2wTM8y8tgodvYUAReference List: https://pharmacytodose.files.wordpress.com/2023/07/copd-references-1.pdfPharmacyToDose.Com @PharmacyToDose PharmacyToDose@Gmail.com Learn more about your ad choices. Visit megaphone.fm/adchoices

COPDSpecial Guest: Ty Kiser, PharmD, FCCM, FCCP, BCCCP, BCPS 03:15 – Background &amp; classification07:10 – AECOPD13:00 – Pharmacotherapy in AECOPD32:40 – Maintenance medications41:55 – Future research / wrap-up  2023 Pharmacy to Dose Awards Ballot: <a href="https://forms.gle/9y2wTM8y8tgodvYUA" rel="nofollow" target="_blank">https://forms.gle/9y2wTM8y8tgodvYUA</a> Reference List: <a href="https://pharmacytodose.files.wordpress.com/2023/07/copd-references-1.pdf" rel="nofollow" target="_blank">https://pharmacytodose.files.wordpress.com/2023/07/copd-references-1.pdf</a> <a href="http://PharmacyToDose.Com" rel="nofollow" target="_blank">PharmacyToDose.Com</a> @PharmacyToDose <a href="mailto:PharmacyToDose@Gmail.com">PharmacyToDose@Gmail.com</a> Learn more about your ad choices. Visit <a href="https://megaphone.fm/adchoices" rel="nofollow" target="_blank">megaphone.fm/adchoices</a>

COPD

BP Control in Neurologic Emergencies Part IISpecial Guest: Andrew Webb, PharmD, BCCCPhttps://www.neurowiserx.com02:25 – Antihypertensive treatment overview10:02 – IV push agents17:47 – Continuous IV agents34:00 – Take-home pointsReference List: https://pharmacytodose.files.wordpress.com/2023/07/bp-in-neurologic-emergencies-part-ii-references.pdfPharmacyToDose.Com @PharmacyToDose PharmacyToDose@Gmail.com Learn more about your ad choices. Visit megaphone.fm/adchoices

BP Control in Neurologic Emergencies Part IISpecial Guest: Andrew Webb, PharmD, BCCCP<a href="https://www.neurowiserx.com/" rel="nofollow" target="_blank">https://www.neurowiserx.com</a> 02:25 – Antihypertensive treatment overview10:02 – IV push agents17:47 – Continuous IV agents34:00 – Take-home points Reference List: <a href="https://pharmacytodose.files.wordpress.com/2023/07/bp-in-neurologic-emergencies-part-ii-references.pdf" rel="nofollow" target="_blank">https://pharmacytodose.files.wordpress.com/2023/07/bp-in-neurologic-emergencies-part-ii-references.pdf</a> <a href="http://PharmacyToDose.Com" rel="nofollow" target="_blank">PharmacyToDose.Com</a> @PharmacyToDose <a href="mailto:PharmacyToDose@Gmail.com">PharmacyToDose@Gmail.com</a> Learn more about your ad choices. Visit <a href="https://megaphone.fm/adchoices" rel="nofollow" target="_blank">megaphone.fm/adchoices</a>

BP Control in Neurologic Emergencies Part II

Blood Pressure Control in Neurologic Emergencies Part ISpecial Guest: Andrew Webb, PharmD, BCCCPhttps://www.neurowiserx.com03:50 – Background/pathophysiology11:30 – AIS &amp; thrombolysis20:10 – AIS &amp; thrombectomy39:35 – Spontaneous intracerebral hemorrhageReference List: https://pharmacytodose.files.wordpress.com/2023/06/bp-in-neurologic-emergencies-part-i-references.pdfPharmacyToDose.Com @PharmacyToDose PharmacyToDose@Gmail.com Learn more about your ad choices. Visit megaphone.fm/adchoices

Blood Pressure Control in Neurologic Emergencies Part ISpecial Guest: Andrew Webb, PharmD, BCCCP<a href="https://www.neurowiserx.com/" rel="nofollow" target="_blank">https://www.neurowiserx.com</a> 03:50 – Background/pathophysiology11:30 – AIS &amp; thrombolysis20:10 – AIS &amp; thrombectomy39:35 – Spontaneous intracerebral hemorrhage Reference List: <a href="https://pharmacytodose.files.wordpress.com/2023/06/bp-in-neurologic-emergencies-part-i-references.pdf" rel="nofollow" target="_blank">https://pharmacytodose.files.wordpress.com/2023/06/bp-in-neurologic-emergencies-part-i-references.pdf</a> <a href="http://PharmacyToDose.Com" rel="nofollow" target="_blank">PharmacyToDose.Com</a> @PharmacyToDose <a href="mailto:PharmacyToDose@Gmail.com">PharmacyToDose@Gmail.com</a> Learn more about your ad choices. Visit <a href="https://megaphone.fm/adchoices" rel="nofollow" target="_blank">megaphone.fm/adchoices</a>

BP Control in Neurologic Emergencies Part I

ESOC 2023 Rapid Reactions: TIMELESS and OPTIMAL-BPSpecial Guest: Leslie Hamilton, PharmD, FCCP, FCCM, FNCS, BCPS, BCCCP 04:15 – TIMELESS trial21:20 – OPTIMAL-BP trialReference List: https://pharmacytodose.files.wordpress.com/2023/06/esoc-2023-rapid-reaction-references.pdfPharmacyToDose.Com @PharmacyToDose PharmacyToDose@Gmail.com Learn more about your ad choices. Visit megaphone.fm/adchoices

ESOC 2023 Rapid Reactions: TIMELESS and OPTIMAL-BP Special Guest: Leslie Hamilton, PharmD, FCCP, FCCM, FNCS, BCPS, BCCCP  04:15 – TIMELESS trial21:20 – OPTIMAL-BP trial Reference List: <a href="https://pharmacytodose.files.wordpress.com/2023/06/esoc-2023-rapid-reaction-references.pdf" rel="nofollow" target="_blank">https://pharmacytodose.files.wordpress.com/2023/06/esoc-2023-rapid-reaction-references.pdf</a> <a href="http://PharmacyToDose.Com" rel="nofollow" target="_blank">PharmacyToDose.Com</a> @PharmacyToDose <a href="mailto:PharmacyToDose@Gmail.com">PharmacyToDose@Gmail.com</a> Learn more about your ad choices. Visit <a href="https://megaphone.fm/adchoices" rel="nofollow" target="_blank">megaphone.fm/adchoices</a>

ESOC 2023 Rapid Reactions: TIMELESS & OPTIMAL-BP

Pharmacy to Dose: The Critical Care Podcast discusses critical care and its pharmacotherapy in a fun and entertaining manner. Each episode features a special guest, a subject matter expert, talking with host Nick Peters.

Good content. Hard to hear the guests-poor sound quality.

Hard to hear in car

The Host’s voice is so sexy!

Pharmacy to Dose: The Critical Care Podcast

Vasoactives in Septic Shock with Special Guest: Alex Flannery, PharmD, BCCCP, BCPS 3:35 – Why is Alex interested in sepsis?...5:49 – How do you teach sepsis with the recent changes?...8:35 – When to start vasopressors in a hypotensive patient?...11:58 – What do you consider high-dose norepinephrine?...13:40 – How do you add vasopressin and corticosteroids for patients in refractory septic shock?...15:15 – Do you use fludricortisone in combination with hydrocortisone?...16:49 – Utility of cortisol levels or ACTH stimulation testing...18:27 – Cost:benefit analysis of vasopressin...19:21 – Role of epinephrine in septic shock...21:15 – Dobutamine or Epinephrine?...22:57 – HAT cocktail...24:55 – Thiamine supplementation in sepsis and septic shock...28:35 – Use of Angiotensin II and its place in therapy...32:30 – Approach to using methylene blue...34:05 – Modify hemodynamic goals to assist with vasopressor weaning...36:07 – Managing adverse effects due to vasopressors...39:27 – Order of operations in weaning vasopressors and corticosteroids...44:35 – The use of midodrine to wean off IV vasopressors...49:25 – Take-away points for vasoactives and their use in septic shock...51:11– Future areas for research   PharmacyToDose.Com @PharmacyToDose on Twitter/Instragram PharmacyToDose@Gmail.com  Learn more about your ad choices. Visit megaphone.fm/adchoices

Vasoactives in Septic Shock with Special Guest: Alex Flannery, PharmD, BCCCP, BCPS 3:35 – Why is Alex interested in sepsis?...5:49 – How do you teach sepsis with the recent changes?...8:35 – When to start vasopressors in a hypotensive patient?...11:58 – What do you consider high-dose norepinephrine?...13:40 – How do you add vasopressin and corticosteroids for patients in refractory septic shock?...15:15 – Do you use fludricortisone in combination with hydrocortisone?...16:49 – Utility of cortisol levels or ACTH stimulation testing...18:27 – Cost:benefit analysis of vasopressin...19:21 – Role of epinephrine in septic shock...21:15 – Dobutamine or Epinephrine?...22:57 – HAT cocktail...24:55 – Thiamine supplementation in sepsis and septic shock...28:35 – Use of Angiotensin II and its place in therapy...32:30 – Approach to using methylene blue...34:05 – Modify hemodynamic goals to assist with vasopressor weaning...36:07 – Managing adverse effects due to vasopressors...39:27 – Order of operations in weaning vasopressors and corticosteroids...44:35 – The use of midodrine to wean off IV vasopressors...49:25 – Take-away points for vasoactives and their use in septic shock...51:11– Future areas for research <a href="http://PharmacyToDose.Com" rel="nofollow" target="_blank">PharmacyToDose.Com</a> @PharmacyToDose on Twitter/Instragram PharmacyToDose@Gmail.com Learn more about your ad choices. Visit <a href="https://megaphone.fm/adchoices" rel="nofollow" target="_blank">megaphone.fm/adchoices</a>

Vasoactives in Septic Shock

Acute Respiratory Distress Syndrome (ARDS)Special Guest: Andrea Sikora Newsome, PharmD, BCPS, BCCCP Show Notes: https://pharmacytodose.files.wordpress.com/2019/12/ards-show-notes.pdfShow References: https://pharmacytodose.files.wordpress.com/2019/12/ards-references.pdf 4:42 – #PharmacyToRead Book Club Announcement!; 7:24 – History of ARDS; 10:17 – Current ARDS definition; 11:25 – Criticisms to Berlin definition; 13:54 – ARDS Causes/Risk factors; 15:33 – Typical ARDS time course; 18:58 – ARDS treatment goals; 21:04 – Brief primer on mechanical ventilation; 30:50 – Prone positioning; 35:17 – NMBA for ARDS; 42:15 – Prone, paralyze, or both?; 43:34 – FACTT study and fluid stewardship in ARDS; 46:00 – Corticosteroids in ARDS; 49:45 – ARDS failed drugs; 53:55 – ECMO for severe ARDS; 58:25 – Future research areas; 60:10 – Role of PharmD in ARDS PharmacyToDose.Com @PharmacyToDose on Twitter/Instagram PharmacyToDose@Gmail.com  Learn more about your ad choices. Visit megaphone.fm/adchoices

Acute Respiratory Distress Syndrome (ARDS) Special Guest: Andrea Sikora Newsome, PharmD, BCPS, BCCCP Show Notes: <a href="https://pharmacytodose.files.wordpress.com/2019/12/ards-show-notes.pdf" rel="nofollow" target="_blank">https://pharmacytodose.files.wordpress.com/2019/12/ards-show-notes.pdf</a> Show References: <a href="https://pharmacytodose.files.wordpress.com/2019/12/ards-references.pdf" rel="nofollow" target="_blank">https://pharmacytodose.files.wordpress.com/2019/12/ards-references.pdf</a> 4:42 – #PharmacyToRead Book Club Announcement!; 7:24 – History of ARDS; 10:17 – Current ARDS definition; 11:25 – Criticisms to Berlin definition; 13:54 – ARDS Causes/Risk factors; 15:33 – Typical ARDS time course; 18:58 – ARDS treatment goals; 21:04 – Brief primer on mechanical ventilation; 30:50 – Prone positioning; 35:17 – NMBA for ARDS; 42:15 – Prone, paralyze, or both?; 43:34 – FACTT study and fluid stewardship in ARDS; 46:00 – Corticosteroids in ARDS; 49:45 – ARDS failed drugs; 53:55 – ECMO for severe ARDS; 58:25 – Future research areas; 60:10 – Role of PharmD in ARDS <a href="http://PharmacyToDose.Com" rel="nofollow" target="_blank">PharmacyToDose.Com</a> @PharmacyToDose on Twitter/Instagram <a href="mailto:PharmacyToDose@Gmail.com">PharmacyToDose@Gmail.com</a> Learn more about your ad choices. Visit <a href="https://megaphone.fm/adchoices" rel="nofollow" target="_blank">megaphone.fm/adchoices</a>

ARDS 

Fluid Stewardship Special Guest: Anthony Hawkins, PharmD, BCCCP Show notes: https://pharmacytodose.files.wordpress.com/2019/11/fluid-stewardship-show-notes.pdf Show references: https://pharmacytodose.files.wordpress.com/2019/11/fluid-stewardship-references.pdf   5:45 – Defining fluid overload; 7:12 – Complications of being fluid overloaded; 10:45 – Why does fluid overload still happen?; 13:40 – Solutions to help fix mIVF; 15:30 – Patients at risk of becoming fluid overloaded; 18:28 – Determining if patients are fluid responsive; 24:38 – Does fluid responsiveness mean always give fluid?; 26:40 – What does fluid stewardship mean?; 28:45 – Four D’s; 31:30 – ROSE model; 39:39 – Applying ROSE model to non-sepsis patients; 42:20 – 4 rights of Medication Administration for Fluid Stewardship; 53:48 – Interventions that Pharmacists can make; 59:49 – Questions that still need answered; 61:30 – Future research to watch for; 63:33 – Take-home points   PharmacyToDose.Com @PharmacyToDose on Twitter/Instagram PharmacyToDose@Gmail.com  Learn more about your ad choices. Visit megaphone.fm/adchoices

Fluid Stewardship Special Guest: Anthony Hawkins, PharmD, BCCCP Show notes: <a href="https://pharmacytodose.files.wordpress.com/2019/11/fluid-stewardship-show-notes.pdf" rel="nofollow" target="_blank">https://pharmacytodose.files.wordpress.com/2019/11/fluid-stewardship-show-notes.pdf</a> Show references: <a href="https://pharmacytodose.files.wordpress.com/2019/11/fluid-stewardship-references.pdf" rel="nofollow" target="_blank">https://pharmacytodose.files.wordpress.com/2019/11/fluid-stewardship-references.pdf</a> 5:45 – Defining fluid overload; 7:12 – Complications of being fluid overloaded; 10:45 – Why does fluid overload still happen?; 13:40 – Solutions to help fix mIVF; 15:30 – Patients at risk of becoming fluid overloaded; 18:28 – Determining if patients are fluid responsive; 24:38 – Does fluid responsiveness mean always give fluid?; 26:40 – What does fluid stewardship mean?; 28:45 – Four D’s; 31:30 – ROSE model; 39:39 – Applying ROSE model to non-sepsis patients; 42:20 – 4 rights of Medication Administration for Fluid Stewardship; 53:48 – Interventions that Pharmacists can make; 59:49 – Questions that still need answered; 61:30 – Future research to watch for; 63:33 – Take-home points <a href="http://PharmacyToDose.Com" rel="nofollow" target="_blank">PharmacyToDose.Com</a> @PharmacyToDose on Twitter/Instagram <a href="mailto:PharmacyToDose@Gmail.com">PharmacyToDose@Gmail.com</a> Learn more about your ad choices. Visit <a href="https://megaphone.fm/adchoices" rel="nofollow" target="_blank">megaphone.fm/adchoices</a>

Fluid Stewardship

Status Epilepticus with Special Guest: Karen Berger, PharmD, FCCM, BCPS, BCCCP Show notes: https://pharmacytodose.files.wordpress.com/2019/10/status-epilepticus-show-notes-1.pdf References: https://pharmacytodose.files.wordpress.com/2019/10/status-epilepticus-references.pdf 6:02 –Karen’s interest in SE; 7:35 – What is SE?; 9:32 – Further classifications of SE?; 10:37 – Patient presentation; 11:27 – Can the presentation change?; 13:35 – Any risk factors for SE?; 14:45 – Medication-induced SE; 15:40 – Prompt non-AED treatment for SE?; 17:06 – Empirically treat Wernicke’s?; 18:35 – Preferred BZD for initial treatment of SE?; 20:44 – If they don’t respond to an AED, do you avoid/discontinue using these agents?; 23:08 – Convincing providers to give larger BZD doses?; 26:53 – BZD dosing if a patient uses alcohol or BZD?; 27:37 – First-line AED for patients in SE?; 30:34 – Difficulty with high quality research in SE?; 31:46 – Are there specific patient populations or disease states where you prefer or avoid a specific AED?; 33:04 – Why is timely treatment so important?; 34:25 – General information on first-line AED agents; 47:20 – Where to find evidence-based dosing recommendations for SE?; 49:49 – Appropriate TDM of AED; 53:55 – Increase dose or add another AED?; 55:53 – How to improve time to AED administration for SE?; 59:04 – Review of IV anesthetic infusions for refractory SE; 64:27 – Tips/Tricks for Pharmacists treating SE; 65:40 – Take-home points PharmacyToDose.Com @PharmacyToDose on Twitter/Instragram PharmacyToDose@Gmail.com  Learn more about your ad choices. Visit megaphone.fm/adchoices

Status Epilepticus with Special Guest: Karen Berger, PharmD, FCCM, BCPS, BCCCP Show notes: <a href="https://pharmacytodose.files.wordpress.com/2019/10/status-epilepticus-show-notes-1.pdf" rel="nofollow" target="_blank">https://pharmacytodose.files.wordpress.com/2019/10/status-epilepticus-show-notes-1.pdf</a> References: <a href="https://pharmacytodose.files.wordpress.com/2019/10/status-epilepticus-references.pdf" rel="nofollow" target="_blank">https://pharmacytodose.files.wordpress.com/2019/10/status-epilepticus-references.pdf</a> 6:02 –Karen’s interest in SE; 7:35 – What is SE?; 9:32 – Further classifications of SE?; 10:37 – Patient presentation; 11:27 – Can the presentation change?; 13:35 – Any risk factors for SE?; 14:45 – Medication-induced SE; 15:40 – Prompt non-AED treatment for SE?; 17:06 – Empirically treat Wernicke’s?; 18:35 – Preferred BZD for initial treatment of SE?; 20:44 – If they don’t respond to an AED, do you avoid/discontinue using these agents?; 23:08 – Convincing providers to give larger BZD doses?; 26:53 – BZD dosing if a patient uses alcohol or BZD?; 27:37 – First-line AED for patients in SE?; 30:34 – Difficulty with high quality research in SE?; 31:46 – Are there specific patient populations or disease states where you prefer or avoid a specific AED?; 33:04 – Why is timely treatment so important?; 34:25 – General information on first-line AED agents; 47:20 – Where to find evidence-based dosing recommendations for SE?; 49:49 – Appropriate TDM of AED; 53:55 – Increase dose or add another AED?; 55:53 – How to improve time to AED administration for SE?; 59:04 – Review of IV anesthetic infusions for refractory SE; 64:27 – Tips/Tricks for Pharmacists treating SE; 65:40 – Take-home points <a href="http://PharmacyToDose.Com" rel="nofollow" target="_blank">PharmacyToDose.Com</a> @PharmacyToDose on Twitter/Instragram PharmacyToDose@Gmail.com Learn more about your ad choices. Visit <a href="https://megaphone.fm/adchoices" rel="nofollow" target="_blank">megaphone.fm/adchoices</a>

Status Epilepticus

Prothrombin Complex Concentrates (PCCs) for PharmDsSpecial Guest: Scott Dietrich, PharmD, BCCCP Show Notes: https://pharmacytodose.files.wordpress.com/2019/12/pccs-for-pharmds-show-notes.pdf Show References: https://pharmacytodose.files.wordpress.com/2019/12/pccs-for-pharmds-references.pdf 3:05 – Anticoagulation reversal pre-PCC5:18 – Brief history of PCC6:45 – Current role for 3-factor PCC7:56 – When should we be using PCC?10:00 – Role of PCC for non-reversal indications13:20 – Weight-based v. Fixed-dose Kcentra15:39 – Why fixed-dose Kcentra?17:33 – When to re-dose Kcentra?18:50 – Kcentra when INR &lt; 220:20 – Guideline-recommended anticoagulation reversal22:30 – How does Kcentra differ from FEIBA?23:48 – FEIBA dosing strategy24:15 – Kcentra for DOAC reversal28:22 – FEIBA for DOAC reversal30:02 – FEIBA v. Kcentra for DOAC reversal30:25 – FEIBA v. KCentra for warfarin reversal33:32 – Should we have Kcentra and FEIBA on formulary?34:26 – Weight-based v. Fixed-dose FEIBA for DOAC reversal35:20 – Pros/Cons of Andexxa37:14 – PCC v. Andexxa37:45 – Andexxa’s cost40:10 – How would Scott reverse his AC?43:20 – Pharmacist’s role45:54 – PCC take home points  PharmacyToDose.Com@PharmacyToDose on Twitter/InstagramPharmacyToDose@Gmail.com  Learn more about your ad choices. Visit megaphone.fm/adchoices

Prothrombin Complex Concentrates (PCCs) for PharmDs Special Guest: Scott Dietrich, PharmD, BCCCP Show Notes: <a href="https://pharmacytodose.files.wordpress.com/2019/12/pccs-for-pharmds-show-notes.pdf" rel="nofollow" target="_blank">https://pharmacytodose.files.wordpress.com/2019/12/pccs-for-pharmds-show-notes.pdf</a> Show References: <a href="https://pharmacytodose.files.wordpress.com/2019/12/pccs-for-pharmds-references.pdf" rel="nofollow" target="_blank">https://pharmacytodose.files.wordpress.com/2019/12/pccs-for-pharmds-references.pdf</a> 3:05 – Anticoagulation reversal pre-PCC 5:18 – Brief history of PCC 6:45 – Current role for 3-factor PCC 7:56 – When should we be using PCC? 10:00 – Role of PCC for non-reversal indications 13:20 – Weight-based v. Fixed-dose Kcentra 15:39 – Why fixed-dose Kcentra? 17:33 – When to re-dose Kcentra? 18:50 – Kcentra when INR &lt; 2 20:20 – Guideline-recommended anticoagulation reversal 22:30 – How does Kcentra differ from FEIBA? 23:48 – FEIBA dosing strategy 24:15 – Kcentra for DOAC reversal 28:22 – FEIBA for DOAC reversal 30:02 – FEIBA v. Kcentra for DOAC reversal 30:25 – FEIBA v. KCentra for warfarin reversal 33:32 – Should we have Kcentra and FEIBA on formulary? 34:26 – Weight-based v. Fixed-dose FEIBA for DOAC reversal 35:20 – Pros/Cons of Andexxa 37:14 – PCC v. Andexxa 37:45 – Andexxa’s cost 40:10 – How would Scott reverse his AC? 43:20 – Pharmacist’s role 45:54 – PCC take home points  <a href="http://PharmacyToDose.Com" rel="nofollow" target="_blank">PharmacyToDose.Com</a> @PharmacyToDose on Twitter/Instagram <a href="mailto:PharmacyToDose@Gmail.com">PharmacyToDose@Gmail.com</a> Learn more about your ad choices. Visit <a href="https://megaphone.fm/adchoices" rel="nofollow" target="_blank">megaphone.fm/adchoices</a>

PCCs for PharmDs

Value &amp; Importance of ICU Pharmacists with Special Guest: Chris Droege, PharmD, BCCCP, FCCM, FASHP Show notes: https://pharmacytodose.files.wordpress.com/2019/10/icu-pharmacist-show-notes.pdf References: https://pharmacytodose.files.wordpress.com/2019/10/icu-pharmacist-references-1.pdf 8:02 – History of Critical Care Pharmacy; 13:40 – Why are Pharmacists needed as multidisciplinary team members?; 15:45 – Why do Pharmacists still need to justify our value?; 18:45 – Historical perception of Pharmacists play a part?; 21:51 – Overview of the White Paper; 26:52 – How relevant are most of these recommendations now?; 30:40 – How should time be spent within the different pillars?; 36:49 – Avoiding “The Sheriff” mentality; 41:55 – Examples of Pharmacists demonstrating value; 45:30 – How do we continue creating research studies demonstrating Pharmacists’ value?; 49:50 – The future of Clinical Pharmacy; 55:45 – Tips/Tricks for Pharmacists to demonstrate value to the ICU team   PharmacyToDose.Com @PharmacyToDose on Twitter/Instagram PharmacyToDose@Gmail.com  Learn more about your ad choices. Visit megaphone.fm/adchoices

Value &amp; Importance of ICU Pharmacists with Special Guest: Chris Droege, PharmD, BCCCP, FCCM, FASHP Show notes: <a href="https://pharmacytodose.files.wordpress.com/2019/10/icu-pharmacist-show-notes.pdf" rel="nofollow" target="_blank">https://pharmacytodose.files.wordpress.com/2019/10/icu-pharmacist-show-notes.pdf</a> References: <a href="https://pharmacytodose.files.wordpress.com/2019/10/icu-pharmacist-references-1.pdf" rel="nofollow" target="_blank">https://pharmacytodose.files.wordpress.com/2019/10/icu-pharmacist-references-1.pdf</a> 8:02 – History of Critical Care Pharmacy; 13:40 – Why are Pharmacists needed as multidisciplinary team members?; 15:45 – Why do Pharmacists still need to justify our value?; 18:45 – Historical perception of Pharmacists play a part?; 21:51 – Overview of the White Paper; 26:52 – How relevant are most of these recommendations now?; 30:40 – How should time be spent within the different pillars?; 36:49 – Avoiding “The Sheriff” mentality; 41:55 – Examples of Pharmacists demonstrating value; 45:30 – How do we continue creating research studies demonstrating Pharmacists’ value?; 49:50 – The future of Clinical Pharmacy; 55:45 – Tips/Tricks for Pharmacists to demonstrate value to the ICU team <a href="http://PharmacyToDose.Com" rel="nofollow" target="_blank">PharmacyToDose.Com</a> @PharmacyToDose on Twitter/Instagram PharmacyToDose@Gmail.com Learn more about your ad choices. Visit <a href="https://megaphone.fm/adchoices" rel="nofollow" target="_blank">megaphone.fm/adchoices</a>

Value and Importance of ICU Pharmacists

Acute Kidney Injury (AKI)Special Guest: Erin Barreto, PharmD, MSc, BCPS, BCCCP, FCCM Show Notes: https://pharmacytodose.files.wordpress.com/2020/02/aki-show-notes.pdf Show References: https://pharmacytodose.files.wordpress.com/2020/02/aki-references.pdf 1:10 – Show updates!; 9:15 – Define and classify AKI; 14:45 – Subspecifying the type of AKI; 18:22 – Prevalence of AKI in the ICU; 20:45 – Identification of high-risk patients; 24:43 – Preferred risk prediction tools; 26:12 – Ideal kidney biomarker; 28:28 – Ideal v. current biomarkers; 32:13 – Structural biomarkers; 39:40 – AKI prevention; 44:08 – Kidney/drug dosing equations; 53:49 – Equations in AKI/renal recovery; 56:43 – Cystatin C; 72:19 – What if you don’t use novel biomarkers?; 75:33 – Favorite calculator for AKI clinical risk predictor tool; 77:43 – AKI potpourri; 85:05 – Take-home points PharmacyToDose.Com@PharmacyToDose on Twitter/InstagramPharmacyToDose@Gmail.com  Learn more about your ad choices. Visit megaphone.fm/adchoices

Acute Kidney Injury (AKI) Special Guest: Erin Barreto, PharmD, MSc, BCPS, BCCCP, FCCM Show Notes: <a href="https://pharmacytodose.files.wordpress.com/2020/02/aki-show-notes.pdf" rel="nofollow" target="_blank">https://pharmacytodose.files.wordpress.com/2020/02/aki-show-notes.pdf</a> Show References: <a href="https://pharmacytodose.files.wordpress.com/2020/02/aki-references.pdf" rel="nofollow" target="_blank">https://pharmacytodose.files.wordpress.com/2020/02/aki-references.pdf</a> 1:10 – Show updates!; 9:15 – Define and classify AKI; 14:45 – Subspecifying the type of AKI; 18:22 – Prevalence of AKI in the ICU; 20:45 – Identification of high-risk patients; 24:43 – Preferred risk prediction tools; 26:12 – Ideal kidney biomarker; 28:28 – Ideal v. current biomarkers; 32:13 – Structural biomarkers; 39:40 – AKI prevention; 44:08 – Kidney/drug dosing equations; 53:49 – Equations in AKI/renal recovery; 56:43 – Cystatin C; 72:19 – What if you don’t use novel biomarkers?; 75:33 – Favorite calculator for AKI clinical risk predictor tool; 77:43 – AKI potpourri; 85:05 – Take-home points <a href="http://PharmacyToDose.Com" rel="nofollow" target="_blank">PharmacyToDose.Com</a> @PharmacyToDose on Twitter/Instagram <a href="mailto:PharmacyToDose@Gmail.com">PharmacyToDose@Gmail.com</a> Learn more about your ad choices. Visit <a href="https://megaphone.fm/adchoices" rel="nofollow" target="_blank">megaphone.fm/adchoices</a>

Acute Kidney Injury

Extracorporeal Membrane Oxygenation (ECMO)Special Guest: Amy Dzierba, PharmD, FCCM, FCCP, BCCCP  Show Notes: https://pharmacytodose.files.wordpress.com/2020/01/ecmo-show-notes.pdfShow References: https://pharmacytodose.files.wordpress.com/2020/01/ecmo-references.pdf  00:25 - #PharmacyToRead Announcement!; 07:50 – Why is Amy interested in ECMO?; 11:48 – What is ECMO and when did we start using ECMO in the US?; 13:45 – ECLS v. ECMO; 15:52 – Why are we talking about ECMO today?; 19:40– What does ECMO do?; 21:05 – ECMO modalities; 22:59 – ECMO equipment; 27:30 – What should be tried before ECMO?; 30:56 – ECLS effect on PK/PD; 40:05 – Tips/tricks on ECMO anticoagulation, infection, and sedation protocols; 40:45 – Anticoagulation protocols; 47:30 – Infection protocols; 53:15 – Sedation protocols; 58:18 – ECMO complications; 60:40 – Tips when creating or modifying ECMO protocols; 63:27 – Future areas of ECMO research; 65:00 – Take-home points PharmacyToDose.Com @PharmacyToDose on Twitter/Instagram PharmacyToDose@Gmail.com  Learn more about your ad choices. Visit megaphone.fm/adchoices

Extracorporeal Membrane Oxygenation (ECMO) Special Guest: Amy Dzierba, PharmD, FCCM, FCCP, BCCCP  Show Notes: <a href="https://pharmacytodose.files.wordpress.com/2020/01/ecmo-show-notes.pdf" rel="nofollow" target="_blank">https://pharmacytodose.files.wordpress.com/2020/01/ecmo-show-notes.pdf</a> Show References: <a href="https://pharmacytodose.files.wordpress.com/2020/01/ecmo-references.pdf" rel="nofollow" target="_blank">https://pharmacytodose.files.wordpress.com/2020/01/ecmo-references.pdf</a> 00:25 - #PharmacyToRead Announcement!; 07:50 – Why is Amy interested in ECMO?; 11:48 – What is ECMO and when did we start using ECMO in the US?; 13:45 – ECLS v. ECMO; 15:52 – Why are we talking about ECMO today?; 19:40– What does ECMO do?; 21:05 – ECMO modalities; 22:59 – ECMO equipment; 27:30 – What should be tried before ECMO?; 30:56 – ECLS effect on PK/PD; 40:05 – Tips/tricks on ECMO anticoagulation, infection, and sedation protocols; 40:45 – Anticoagulation protocols; 47:30 – Infection protocols; 53:15 – Sedation protocols; 58:18 – ECMO complications; 60:40 – Tips when creating or modifying ECMO protocols; 63:27 – Future areas of ECMO research; 65:00 – Take-home points <a href="http://PharmacyToDose.Com" rel="nofollow" target="_blank">PharmacyToDose.Com</a> @PharmacyToDose on Twitter/Instagram <a href="mailto:PharmacyToDose@Gmail.com">PharmacyToDose@Gmail.com</a> Learn more about your ad choices. Visit <a href="https://megaphone.fm/adchoices" rel="nofollow" target="_blank">megaphone.fm/adchoices</a>

ECMO 

Life After the ICU: A Personal ExperienceSpecial Guest: G. Morgan Jones, PharmD, BCCCP, FCCM Show Notes: https://pharmacytodose.files.wordpress.com/2020/01/life-after-the-icu-show-notes.pdf Morgan details his incredible journey after a personal experience with PICS and PICS-F. PharmacyToDose.Com@PharmacyToDose on Twitter/InstagramPharmacyToDose@Gmail.com  Learn more about your ad choices. Visit megaphone.fm/adchoices

Life After the ICU: A Personal Experience Special Guest: G. Morgan Jones, PharmD, BCCCP, FCCM Show Notes: <a href="https://pharmacytodose.files.wordpress.com/2020/01/life-after-the-icu-show-notes.pdf" rel="nofollow" target="_blank">https://pharmacytodose.files.wordpress.com/2020/01/life-after-the-icu-show-notes.pdf</a> Morgan details his incredible journey after a personal experience with PICS and PICS-F. <a href="http://PharmacyToDose.Com" rel="nofollow" target="_blank">PharmacyToDose.Com</a> @PharmacyToDose on Twitter/Instagram <a href="mailto:PharmacyToDose@Gmail.com">PharmacyToDose@Gmail.com</a> Learn more about your ad choices. Visit <a href="https://megaphone.fm/adchoices" rel="nofollow" target="_blank">megaphone.fm/adchoices</a>

Life After the ICU: A Personal Experience

Immunotherapy Toxicity in the ICUSpecial Guest: Heather May, PharmD, FCCM, BCPS, BCCCP  Show Notes: https://pharmacytodose.files.wordpress.com/2020/03/immunotherapy-toxicity-in-the-icu-show-notes.pdf Show References: https://pharmacytodose.files.wordpress.com/2020/03/immunotherapy-references.pdf 00:52 – Show updates!; 10:50 – Immune system primer; 13:30 – How does CART therapy work?; 16:35 – CART Side effects that lead to the ICU; 17:40 – When does CRS occur and how acute is the presentation?; 20:50 – CRS risk factors; 23:26 – Biomarkers for CRS identification; 25:25 – CRS treatment; 32:30 – CART neurotoxicity; 37:00 – Mechanism of ICANS; 38:00 – ICANS risk factors; 39:30 – ICANS treatment; 42:45 – Where do patients go post-CART?; 47:15 – Examples of immune checkpoint inhibitors; 49:27 – ICI mechanism of action; 51:05 – Immune-related adverse events (irAEs); 55:20 – Which irAEs grades will present to the hospital/ICU?; 57:30 – When do irAEs occur?; 59:28 – irAEs treatment; 64:55 – Downside to treating irAEs?; 68:22 – Do irAEs mean the treatment is working?; 73:12 – Take-home points for immunotherapy toxicity PharmacyToDose.Com @PharmacyToDose on Twitter/Instagram PharmacyToDose@Gmail.com  Learn more about your ad choices. Visit megaphone.fm/adchoices

Immunotherapy Toxicity in the ICU Special Guest: Heather May, PharmD, FCCM, BCPS, BCCCP  Show Notes: <a href="https://pharmacytodose.files.wordpress.com/2020/03/immunotherapy-toxicity-in-the-icu-show-notes.pdf" rel="nofollow" target="_blank">https://pharmacytodose.files.wordpress.com/2020/03/immunotherapy-toxicity-in-the-icu-show-notes.pdf</a> Show References: <a href="https://pharmacytodose.files.wordpress.com/2020/03/immunotherapy-references.pdf" rel="nofollow" target="_blank">https://pharmacytodose.files.wordpress.com/2020/03/immunotherapy-references.pdf</a> 00:52 – Show updates!; 10:50 – Immune system primer; 13:30 – How does CART therapy work?; 16:35 – CART Side effects that lead to the ICU; 17:40 – When does CRS occur and how acute is the presentation?; 20:50 – CRS risk factors; 23:26 – Biomarkers for CRS identification; 25:25 – CRS treatment; 32:30 – CART neurotoxicity; 37:00 – Mechanism of ICANS; 38:00 – ICANS risk factors; 39:30 – ICANS treatment; 42:45 – Where do patients go post-CART?; 47:15 – Examples of immune checkpoint inhibitors; 49:27 – ICI mechanism of action; 51:05 – Immune-related adverse events (irAEs); 55:20 – Which irAEs grades will present to the hospital/ICU?; 57:30 – When do irAEs occur?; 59:28 – irAEs treatment; 64:55 – Downside to treating irAEs?; 68:22 – Do irAEs mean the treatment is working?; 73:12 – Take-home points for immunotherapy toxicity <a href="http://PharmacyToDose.Com" rel="nofollow" target="_blank">PharmacyToDose.Com</a> @PharmacyToDose on Twitter/Instagram <a href="mailto:PharmacyToDose@Gmail.com">PharmacyToDose@Gmail.com</a> Learn more about your ad choices. Visit <a href="https://megaphone.fm/adchoices" rel="nofollow" target="_blank">megaphone.fm/adchoices</a>

Immunotherapy Toxicity in the ICU

Post-Intensive Care Syndrome (PICS)Special Guest: Jimmi Hatton Kolpek, PharmD, BSPharm, FCCP, FCCM, FNAP Show Notes: https://pharmacytodose.files.wordpress.com/2020/01/pics-show-notes.pdf Show References: https://pharmacytodose.files.wordpress.com/2020/01/pics-references.pdf 00:25 - #PharmacyToRead Update; 10:07 – Why Jimmi is interested in PICS; 12:36 – When did PICS become an ICU focus?; 13:56 – How did PICS get thrust into the spotlight?; 15:40 – Definition of PICS; 16:27 – When does PICS occur?; 19:38 – How common is PICS?; 21:30 – PICS risk factors; 25:35 – How long does PICS last and how does it affect recovery?; 28:55 – Role of peer support; 31:20 – PICS prevention; 38:17 – Medications that can treat/prevent PICS; 41:50 – When to seek help for PICS?; 44:25 – Process for patients being referred to ICU Recovery Clinic; 48:12 – Who makes up the team and what problems are addressed?; 51:18 – What PICS resources are available for patients/families?; 54:35 – Do we prepare patients for what happens after the ICU?; 56:58 – How can we improve?; 59:53 – Take-home points on PICS PharmacyToDose.Com @PharmacyToDose on Twitter/Instagram PharmacyToDose@Gmail.com  Learn more about your ad choices. Visit megaphone.fm/adchoices

Post-Intensive Care Syndrome (PICS) Special Guest: Jimmi Hatton Kolpek, PharmD, BSPharm, FCCP, FCCM, FNAP Show Notes: <a href="https://pharmacytodose.files.wordpress.com/2020/01/pics-show-notes.pdf" rel="nofollow" target="_blank">https://pharmacytodose.files.wordpress.com/2020/01/pics-show-notes.pdf</a> Show References: <a href="https://pharmacytodose.files.wordpress.com/2020/01/pics-references.pdf" rel="nofollow" target="_blank">https://pharmacytodose.files.wordpress.com/2020/01/pics-references.pdf</a> 00:25 - #PharmacyToRead Update; 10:07 – Why Jimmi is interested in PICS; 12:36 – When did PICS become an ICU focus?; 13:56 – How did PICS get thrust into the spotlight?; 15:40 – Definition of PICS; 16:27 – When does PICS occur?; 19:38 – How common is PICS?; 21:30 – PICS risk factors; 25:35 – How long does PICS last and how does it affect recovery?; 28:55 – Role of peer support; 31:20 – PICS prevention; 38:17 – Medications that can treat/prevent PICS; 41:50 – When to seek help for PICS?; 44:25 – Process for patients being referred to ICU Recovery Clinic; 48:12 – Who makes up the team and what problems are addressed?; 51:18 – What PICS resources are available for patients/families?; 54:35 – Do we prepare patients for what happens after the ICU?; 56:58 – How can we improve?; 59:53 – Take-home points on PICS <a href="http://PharmacyToDose.Com" rel="nofollow" target="_blank">PharmacyToDose.Com</a> @PharmacyToDose on Twitter/Instagram <a href="mailto:PharmacyToDose@Gmail.com">PharmacyToDose@Gmail.com</a> Learn more about your ad choices. Visit <a href="https://megaphone.fm/adchoices" rel="nofollow" target="_blank">megaphone.fm/adchoices</a>

PICS 

2020 SCCM Congress Recap Special Guest and Official Conference Correspondent: Anthony Hawkins, PharmD, BCCCP Anthony and I recap the 2020 SCCM Congress discussing everything from the convention center, research presentations, educational sessions, receptions, things we would change, and much more! This episode was recorded live in Orlando, FL. Show references: https://pharmacytodose.files.wordpress.com/2020/02/2020-sccm-congress-references.pdf PharmacyToDose.Com @PharmacyToDose on Twitter/Instagram PharmacyToDose@Gmail.com    Learn more about your ad choices. Visit megaphone.fm/adchoices

2020 SCCM Congress Recap Special Guest and Official Conference Correspondent: Anthony Hawkins, PharmD, BCCCP Anthony and I recap the 2020 SCCM Congress discussing everything from the convention center, research presentations, educational sessions, receptions, things we would change, and much more! This episode was recorded live in Orlando, FL. Show references: <a href="https://pharmacytodose.files.wordpress.com/2020/02/2020-sccm-congress-references.pdf" rel="nofollow" target="_blank">https://pharmacytodose.files.wordpress.com/2020/02/2020-sccm-congress-references.pdf</a> <a href="http://PharmacyToDose.Com" rel="nofollow" target="_blank">PharmacyToDose.Com</a> @PharmacyToDose on Twitter/Instagram PharmacyToDose@Gmail.com Learn more about your ad choices. Visit <a href="https://megaphone.fm/adchoices" rel="nofollow" target="_blank">megaphone.fm/adchoices</a>

2020 SCCM Congress Recap

Part 1: Critical Care Medication March Madness Bracket  Downloadable bracket and more available here: https://pharmacytodose.com/2020/03/15/2020-critical-care-medication-march-madness-bracket-and-info/ 00:58 – Bracket announcement, background, rules, and how you can participate!; 10:15 – Cardiac region analysis with Matt Rubertus, PharmD, BCCCP; 40:37 – Infectious Diseases region analysis with Josiah Smith, PharmD, BCCCP PharmacyToDose.Com@PharmacyToDose on Twitter/InstagramPharmacyToDose@Gmail.com  Learn more about your ad choices. Visit megaphone.fm/adchoices

Part 1: Critical Care Medication March Madness Bracket  Downloadable bracket and more available here: <a href="https://pharmacytodose.com/2020/03/15/2020-critical-care-medication-march-madness-bracket-and-info/" rel="nofollow" target="_blank">https://pharmacytodose.com/2020/03/15/2020-critical-care-medication-march-madness-bracket-and-info/</a> 00:58 – Bracket announcement, background, rules, and how you can participate!; 10:15 – Cardiac region analysis with Matt Rubertus, PharmD, BCCCP; 40:37 – Infectious Diseases region analysis with Josiah Smith, PharmD, BCCCP <a href="http://PharmacyToDose.Com" rel="nofollow" target="_blank">PharmacyToDose.Com</a> @PharmacyToDose on Twitter/Instagram PharmacyToDose@Gmail.com Learn more about your ad choices. Visit <a href="https://megaphone.fm/adchoices" rel="nofollow" target="_blank">megaphone.fm/adchoices</a>

Part 1: Critical Care Medication March Madness Bracket

Critical Care Management of COVID-19 Special Guests: Drayton Hammond, PharmD, MBA, MSc, BCPS, BCCCP, FCCM Peter Nikolos, PharmD   Show Notes: https://pharmacytodose.files.wordpress.com/2020/04/covid-19-complications-show-notes.pdf   Mechanical Ventilation (Drayton) 08:00 – Non-COVID-19 PAD management; 11:16 – COVID-19 PAD management; 18:22 – Managing PAD drug shortages; 22:38 – Opioid conservation strategies; 26:08 – Propofol conservation strategies; 29:08 – Hypertriglyceridemia with propofol; 32:10 – Risk of PRIS; 34:30 – Ketamine; 41:05 – NMBA use and shortage; 46:00 – PPE conservation; 49:00 – Bronchodilator use for COVID-19; 50:28 – Inhaled anticoagulants; 52:46 – Inhaled pulmonary vasodilators; 54:17 – Advice for COVID-19 management   Cardiovascular (Peter) 67:20 – Current shortages; 71:05 – First-line vasopressor; 73:25 – Vasopressor compounding and utilization changes; 74:50 – Smart pump management; 77:15 – Vasopressor shortage management; 79:45 – Anticoagulation treatment strategy; 85:30 – Anticoagulation monitoring; 86:28 – Anticoagulation in ECMO/CRRT; 88:20 – PE causing rapid decompensation?; 90:25 – Alternate anticoagulants; 92:52 – Thrombolytics in ACS; 98:13 – Code response changes; 100:05 – ACE-I/ARB use in COVID-19; 103:41 – NSAID use in COVID-19; 105:15 – Statin use in COVID-19; 107:25 – Challenges from virtual rounding; 110:20 – Key points on COVID-19 management   PharmacyToDose.Com @PharmacyToDose on Twitter/Instagram PharmacyToDose@Gmail.com  Learn more about your ad choices. Visit megaphone.fm/adchoices

Critical Care Management of COVID-19 Special Guests: Drayton Hammond, PharmD, MBA, MSc, BCPS, BCCCP, FCCM Peter Nikolos, PharmD Show Notes: <a href="https://pharmacytodose.files.wordpress.com/2020/04/covid-19-complications-show-notes.pdf" rel="nofollow" target="_blank">https://pharmacytodose.files.wordpress.com/2020/04/covid-19-complications-show-notes.pdf</a> Mechanical Ventilation (Drayton) 08:00 – Non-COVID-19 PAD management; 11:16 – COVID-19 PAD management; 18:22 – Managing PAD drug shortages; 22:38 – Opioid conservation strategies; 26:08 – Propofol conservation strategies; 29:08 – Hypertriglyceridemia with propofol; 32:10 – Risk of PRIS; 34:30 – Ketamine; 41:05 – NMBA use and shortage; 46:00 – PPE conservation; 49:00 – Bronchodilator use for COVID-19; 50:28 – Inhaled anticoagulants; 52:46 – Inhaled pulmonary vasodilators; 54:17 – Advice for COVID-19 management Cardiovascular (Peter) 67:20 – Current shortages; 71:05 – First-line vasopressor; 73:25 – Vasopressor compounding and utilization changes; 74:50 – Smart pump management; 77:15 – Vasopressor shortage management; 79:45 – Anticoagulation treatment strategy; 85:30 – Anticoagulation monitoring; 86:28 – Anticoagulation in ECMO/CRRT; 88:20 – PE causing rapid decompensation?; 90:25 – Alternate anticoagulants; 92:52 – Thrombolytics in ACS; 98:13 – Code response changes; 100:05 – ACE-I/ARB use in COVID-19; 103:41 – NSAID use in COVID-19; 105:15 – Statin use in COVID-19; 107:25 – Challenges from virtual rounding; 110:20 – Key points on COVID-19 management <a href="http://PharmacyToDose.Com" rel="nofollow" target="_blank">PharmacyToDose.Com</a> @PharmacyToDose on Twitter/Instagram <a href="mailto:PharmacyToDose@Gmail.com">PharmacyToDose@Gmail.com</a> Learn more about your ad choices. Visit <a href="https://megaphone.fm/adchoices" rel="nofollow" target="_blank">megaphone.fm/adchoices</a>

Critical Care Management of COVID-19

Research Principles for COVID-19 Special Guest: Todd Miano, PharmD, PhD   Show Notes: https://pharmacytodose.files.wordpress.com/2020/04/research-principles-show-notes.pdf   05:19 – Todd’s interest in research/statistics; 09:18 – How Todd analyzes a research article; 24:22 – Why so much low-quality research for COVID-19?; 28:18 – In vitro v. in vivo; 32:34 – Risk of study errors in low-quality research; 45:43 – Publication bias; 51:50 – Interpreting outcome-based studies when patients are still critically ill; 54:46 – Ideal primary outcome for COVID-19 trials; 57:50 – Applying information from international data to US patients; 61:02 – What is the risk of using experimental drug treatments?; 68:54 – Effect of COVID-19 on non-COVID research; 70:33 – Advice for starting COVID-19 research; 73:43 – Research red flags; 75:46 – Keeping up with COVID-19 literature; 79:09 – Quarantine entertainment recommendations   PharmacyToDose.Com   @PharmacyToDose on Twitter/Instagram   PharmacyToDose@Gmail.com  Learn more about your ad choices. Visit megaphone.fm/adchoices

Research Principles for COVID-19 Special Guest: Todd Miano, PharmD, PhD Show Notes: <a href="https://pharmacytodose.files.wordpress.com/2020/04/research-principles-show-notes.pdf" rel="nofollow" target="_blank">https://pharmacytodose.files.wordpress.com/2020/04/research-principles-show-notes.pdf</a> 05:19 – Todd’s interest in research/statistics; 09:18 – How Todd analyzes a research article; 24:22 – Why so much low-quality research for COVID-19?; 28:18 – In vitro v. in vivo; 32:34 – Risk of study errors in low-quality research; 45:43 – Publication bias; 51:50 – Interpreting outcome-based studies when patients are still critically ill; 54:46 – Ideal primary outcome for COVID-19 trials; 57:50 – Applying information from international data to US patients; 61:02 – What is the risk of using experimental drug treatments?; 68:54 – Effect of COVID-19 on non-COVID research; 70:33 – Advice for starting COVID-19 research; 73:43 – Research red flags; 75:46 – Keeping up with COVID-19 literature; 79:09 – Quarantine entertainment recommendations <a href="http://PharmacyToDose.Com" rel="nofollow" target="_blank">PharmacyToDose.Com</a> @PharmacyToDose on Twitter/Instagram <a href="mailto:PharmacyToDose@Gmail.com">PharmacyToDose@Gmail.com</a> Learn more about your ad choices. Visit <a href="https://megaphone.fm/adchoices" rel="nofollow" target="_blank">megaphone.fm/adchoices</a>

Research Principles for COVID-19

The best podcast episodes on romantic relationships. Episodes talk about the 5 love languages, intimacy, and the taboo topics of sexual desires and infidelity. This topic is a deep dive into the science and complexities that face us in our relationships with others. Add episodes you're interested into your queue below!

Best Episodes on Relationships & Love

The best podcasts about ourselves as well as the world through the lense of Science. Specific topics include things about our brain, emotions to biology, physics and more!